Proactive Investors - Run By Investors For Investors

ImmuPharma chair hails “successful” recruitment for Lupuzor trials

Tim McCarthy, chairman of ImmuPharma (LON:IMM) says dosing of patients as part of the phase III clinical trial of its lead drug candidate has started in the US.
The pharmaceutical company hopes to recruit 200 sufferers of the life-threatening autoimmune disease Lupus into the study across the US and Europe by the end of 2016.  
No side effects were revealed in previous studies and McCarthy tells Proactive “if that continues through, and we’re very confident it will, and demonstrates that in phase III, I think we should have a very competitive drug in Lupuzor.”

Meet Sayona Mining Ltd, Lithium Power International Ltd, Elementos, Tyranna Resources and Argent Minerals Ltd at our event, Melbourne, 25 July 2017. Register here »
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future ImmuPharma PLC articles
View full IMM profile View Profile

ImmuPharma PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use